Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China ...Middle East

DURHAM, N.C. and BEIJING, March 29, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced...

Hence then, the article about brii bio announces strategic partnership with sinopharm to advance commercialization of long acting covid 19 neutralizing antibody therapy amubarvimab romlusevimab combination in china was published today ( Wednesday 30/03/2022 - 03:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China )

Also on site :

• Road over canal in Penkridge closed as bridge reportedly collapses
• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• 2 found dead after family disturbance reported in Concord